Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.32 |
| ▸ | F11 | P03951 | 7/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615697 | 0.76 | F11 (0.46) | EGFRAAK1F11MAPT | |
| SCHEMBL29053532 | 0.76 | F11 (0.46) | EGFRAAK1F11MAPT | |
| SCHEMBL616050 | 0.71 | SREBF2 (0.44) | AAK1F11MAP4K4CYP17A1 | |
| SCHEMBL613660 | 0.71 | SUV39H2 (0.33) | F11 | |
| SCHEMBL14691373 | 0.70 | SREBF2 (0.45) | AAK1F11MAP4K4MAPTCYP17A1 | |
| SCHEMBL614294 | 0.70 | TNIK (0.33) | AAK1MAP4K4CYP17A1 | |
| SCHEMBL616861 | 0.69 | ATR (0.36) | MAPTTDP1 | |
| SCHEMBL616966 | 0.68 | SREBF2 (0.40) | AAK1MAP4K4 | |
| SCHEMBL614085 | 0.67 | GSK3B (0.36) | MAPTTDP1 | |
| SCHEMBL18797066 | 0.67 | F11 (0.41) | EGFRF11NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| CN-107973809-B | Macrocyclic compounds as factor XIA inhibitors | 百时美施贵宝公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3070087-B1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| EP-2739628-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2739625-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013022818-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013022814-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2534152-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011100402-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | EGFR 928/4885AAK1 641/4885F11 4/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | EGFR 1008/4885AAK1 896/4885F11 3/4885 |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | EGFR 1008/4885AAK1 896/4885F11 3/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | EGFR 987/4885AAK1 900/4885F11 4/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | EGFR 1008/4885AAK1 896/4885F11 3/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | EGFR 1008/4885AAK1 896/4885F11 3/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | EGFR 1008/4885AAK1 896/4885F11 3/4885 |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | EGFR 1008/4885AAK1 896/4885F11 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.